Cutaneous Squamous Cell Carcinoma (cSCC) Market Anticipated To Grow Steadily, Supported By Demand Drivers And Key Industry Trends.

 

How Does The Expected Cutaneous Squamous Cell Carcinoma (cSCC) Market Size In 2030Compare With Its Size In 2026?
 The cutaneous squamous cell carcinoma (cscc) market size has grown strongly in recent years. It will grow from $7.87 billion in 2025 to $8.33 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to high uv exposure rates, aging population growth, increased skin cancer awareness, reliance on surgical excision, hospital-based oncology care.
 
 The cutaneous squamous cell carcinoma (cscc) market size is expected to see strong growth in the next few years. It will grow to $10.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in skin cancer diagnostics, rising adoption of outpatient procedures, growth of dermatologic oncology centers, improved access to early detection, development of targeted therapies. Major trends in the forecast period include rising adoption of mohs micrographic surgery, increased use of non-surgical therapies, growth of early skin cancer screening, expansion of outpatient cancer treatment, focus on minimally invasive procedures.
 
 Claim Your Free Report Sample Today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=21163&type=smp
 
 Which Major Drivers Are Strengthening Demand In The Cutaneous Squamous Cell Carcinoma (cSCC) Market?
 The growing awareness about skin cancer is projected to propel the growth of the cutaneous squamous cell carcinoma (cSCC) market going forward. Skin cancer is the abnormal growth of skin cells, often caused by excessive UV exposure, and can range from harmless to life-threatening. The growing awareness about skin cancer is due to increased public health campaigns, improved access to information, and a rising emphasis on early detection and prevention, leading to greater demand for diagnostic and treatment solutions. Cutaneous squamous cell carcinoma (cSCC) is useful for advancing skin cancer care by enabling targeted therapies, improving diagnosis, and enhancing patient outcomes, ultimately supporting better disease management. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there were 104,930 reported cases of skin cancer in 2023, reflecting a 3.2% increase from the 108,270 cases reported in 2022. Therefore, growing awareness about skin cancer will fuel growth in the cutaneous squamous cell carcinoma (cSCC) market.
 
 How Is The Cutaneous Squamous Cell Carcinoma (cSCC) Market Divided Across Its Major Segment Categories?
 The cutaneous squamous cell carcinoma (cscc) market covered in this report is segmented — 
 
 1) By Treatment: Surgical Treatment, Non-Surgical Treatment
 2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy
 3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications
 
 Subsegments:
 1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication 
 2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies
 
 What Trends Are Projected To Impact The Cutaneous Squamous Cell Carcinoma (cSCC) Market In The Coming Years?
 Major companies operating in the cutaneous squamous cell carcinoma (cSCC) market are focusing on advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted therapies, to improve patient outcomes and provide effective solutions for managing advanced skin cancer. PD-L1, or programmed death-ligand 1, is a protein that suppresses the immune response by binding to PD-1 receptors on T-cells, helping cancer cells evade immune detection. For instance, in December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, received the FDA approval for Unloxcyt (cosibelimab-ipdl). The innovation lies in its ability to block PD-L1, enhancing the immune system’s ability to fight cancer while offering a safer and more effective treatment option. Additionally, its dual mechanisms of action provide a promising approach for managing advanced cutaneous squamous cell carcinoma (cSCC). The approval was based on results from the CK-301–101 trial, which demonstrated clinically meaningful objective response rates and durable responses in patients with advanced cSCC.
 
 Which Influential Players Dominate The Competitive Environment Of The Cutaneous Squamous Cell Carcinoma (cSCC) Market?
 Major companies operating in the cutaneous squamous cell carcinoma (cscc) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., Vidac Pharma Inc., Pfizer Inc., AstraZeneca plc, AbbVie Inc., Johnson & Johnson, Bayer AG, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd. 
 
 Get Your In-Depth Cutaneous Squamous Cell Carcinoma (cSCC) Market Report Now:
 https://www.thebusinessresearchcompany.com/report/cutaneous-squamous-cell-carcinoma-cscc-global-market-report
 
 Which Geographic Markets Are Contributing Most Significantly To The Progress Of The Cutaneous Squamous Cell Carcinoma (cSCC) Market?
 North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cutaneous squamous cell carcinoma (cscc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: info@tbrc.info 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company